Alpha-dystroglycan binding peptide A2G80-modified stealth liposomes as a muscle-targeting carrier for Duchenne muscular dystrophy.

[1]  E. Olson,et al.  Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing , 2020, Nature Communications.

[2]  M. Akaaboune,et al.  The role of the dystrophin glycoprotein complex on the neuromuscular system , 2020, Neuroscience Letters.

[3]  Y. Negishi,et al.  Laminin-derived peptides: Applications in drug delivery systems for targeting. , 2019, Pharmacology & therapeutics.

[4]  P. Cullis,et al.  Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. , 2019, Accounts of chemical research.

[5]  P. Cullis,et al.  A robust microfluidic technology and a new lipid composition for fabrication of curcumin-loaded liposomes: Effect on the anticancer activity and safety of cisplatin. , 2019, Molecular pharmaceutics.

[6]  Jamie L. Marshall,et al.  Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy. , 2019, JCI insight.

[7]  M. Ferrer,et al.  Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy. , 2019, Human molecular genetics.

[8]  P. Erbacher,et al.  Non-Viral Vector Mediated Gene Delivery: the Outsider to Watch Out For in Gene Therapy , 2019, Cell and Gene Therapy Insights.

[9]  S. Takeda,et al.  Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle , 2019, Molecular therapy. Nucleic acids.

[10]  Y. Negishi,et al.  Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections. , 2018, Biological & pharmaceutical bulletin.

[11]  J. Tucker,et al.  Expression of glycosylated α‐dystroglycan in newborn skeletal and cardiac muscles of fukutin related protein (FKRP) mutant mice , 2017, Muscle & nerve.

[12]  A. Fayssoil,et al.  Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy , 2017, Journal of neuromuscular diseases.

[13]  L. Zechiedrich,et al.  Advances in Non-Viral DNA Vectors for Gene Therapy , 2017, Genes.

[14]  Huali Chen,et al.  PCM and TAT co-modified liposome with improved myocardium delivery: in vitro and in vivo evaluations , 2017, Drug delivery.

[15]  S. Takeda,et al.  Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors , 2016, Drug design, development and therapy.

[16]  John M. Shelton,et al.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy , 2016, Science.

[17]  B. Byrne,et al.  Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy , 2015, Annals of neurology.

[18]  E. Hoffman,et al.  The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse , 2015, Toxicology reports.

[19]  Yvonne Perrie,et al.  Microfluidic-controlled manufacture of liposomes for the solubilisation of a poorly water soluble drug. , 2015, International journal of pharmaceutics.

[20]  T. Okazaki,et al.  Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2 , 2014, EMBO molecular medicine.

[21]  J. Mendell,et al.  Eteplirsen for the treatment of Duchenne muscular dystrophy , 2013, Annals of neurology.

[22]  T. Yokota,et al.  Antisense Therapy in Neurology , 2013, Journal of personalized medicine.

[23]  Xiao Xiao,et al.  Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes , 2013, Human Genetics.

[24]  Thomas Krucker,et al.  Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.

[25]  Nathan M Belliveau,et al.  Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA , 2012, Molecular therapy. Nucleic acids.

[26]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[27]  M. Hagiwara,et al.  Chemical treatment enhances skipping of a mutated exon in the dystrophin gene , 2011, Nature communications.

[28]  M. Nomizu,et al.  Identification of alpha-dystroglycan binding sequences in the laminin alpha2 chain LG4-5 module. , 2010, Matrix biology : journal of the International Society for Matrix Biology.

[29]  A. Nakamura,et al.  Exon‐skipping therapy for Duchenne muscular dystrophy , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[30]  Juan Li,et al.  A muscle-targeting peptide displayed on AAV2 improves muscle tropism upon systemic delivery , 2009, Gene Therapy.

[31]  P. Iversen,et al.  Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. , 2007, Bioconjugate chemistry.

[32]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[33]  S. Peltz,et al.  Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult Volunteers , 2007, Journal of clinical pharmacology.

[34]  S. Futaki,et al.  Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature. , 2006, Biochimica et biophysica acta.

[35]  S. Hirota,et al.  Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome. , 2002, International journal of pharmaceutics.

[36]  R. Gaspar,et al.  Use of the Post-Insertion Technique to Insert Peptide Ligands into Pre-Formed Stealth Liposomes with Retention of Binding Activity and Cytotoxicity , 2002, Pharmaceutical Research.

[37]  M. Grounds,et al.  Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability , 2002, Journal of anatomy.

[38]  S. Futaki,et al.  Arginine-rich Peptides , 2001, The Journal of Biological Chemistry.

[39]  K. Campbell,et al.  Molecular basis of muscular dystrophies , 2000, Muscle & nerve.

[40]  S. Orcesi,et al.  A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy , 2000, Muscle & nerve.

[41]  A. Nishikawa,et al.  Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. , 1995, Journal of biochemistry.

[42]  A. Utani,et al.  Identification of Cell Binding Sites in the Laminin α1 Chain Carboxyl-terminal Globular Domain by Systematic Screening of Synthetic Peptides (*) , 1995, The Journal of Biological Chemistry.

[43]  A. Emery.  Population frequencies of inherited neuromuscular diseases—A world survey , 1991, Neuromuscular Disorders.

[44]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[45]  Giulia Anderluzzi,et al.  Microfluidics based manufacture of liposomes simultaneously entrapping hydrophilic and lipophilic drugs. , 2016, International journal of pharmaceutics.